LXEO
Price
$2.63
Change
-$0.11 (-4.01%)
Updated
Oct 14 closing price
Capitalization
257.76M
60 days until earnings call
Intraday BUY SELL Signals
MLYS
Price
$20.76
Change
-$0.24 (-1.14%)
Updated
Oct 14 closing price
Capitalization
2.27B
32 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LXEO vs MLYS

LXEO vs MLYS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LXEO vs. MLYS commentary
Oct 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXEO is a Hold and MLYS is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LXEO with price predictions
Oct 14, 2026

LXEO in downward trend: price dove below 50-day moving average on September 09, 2026

LXEO moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend. In 21 of 23 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day moving average for LXEO crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for LXEO entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +0.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where LXEO advanced for three days, in 152 of 175 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

LXEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 59 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.097) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. LXEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for MLYS with price predictions
Oct 14, 2026

MLYS's Indicator enters downward trend

The Aroon Indicator for MLYS entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 171 similar instances where the Aroon Indicator formed such a pattern. In 149 of the 171 cases the stock moved lower. This puts the odds of a downward move at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MLYS as a result. In 46 of 58 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.

The Moving Average Convergence Divergence Histogram (MACD) for MLYS turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 35 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

MLYS moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MLYS crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLYS advanced for three days, in 167 of 195 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

MLYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.114) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MLYS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLYS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
LXEOMLYS
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
N/A
Bearish Trend 1 day ago
79%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 27 days ago
87%
Bullish Trend 6 days ago
86%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
87%
COMPARISON
Comparison
Oct 15, 2026
Stock price -- (LXEO: $2.63 vs. MLYS: $20.76)
Brand notoriety: LXEO and MLYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXEO: 154% vs. MLYS: 80%
Market capitalization -- LXEO: $257.76M vs. MLYS: $2.27B
LXEO [@Biotechnology] is valued at $257.76M. MLYS’s [@Biotechnology] market capitalization is $2.27B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXEO’s FA Score shows that 0 FA rating(s) are green while MLYS’s FA Score has 0 green FA rating(s).

  • LXEO’s FA Score: 0 green, 5 red.
  • MLYS’s FA Score: 0 green, 5 red.
According to our system of comparison, MLYS is a better buy in the long-term than LXEO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXEO’s TA Score shows that 4 TA indicator(s) are bullish while MLYS’s TA Score has 4 bullish TA indicator(s).

  • LXEO’s TA Score: 4 bullish, 4 bearish.
  • MLYS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, LXEO is a better buy in the short-term than MLYS.

Price Growth

LXEO (@Biotechnology) experienced а -20.54% price change this week, while MLYS (@Biotechnology) price change was -6.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.52%. For the same industry, the average monthly price growth was -19.04%, and the average quarterly price growth was -19.99%.

Reported Earning Dates

LXEO is expected to report earnings on Dec 14, 2026.

MLYS is expected to report earnings on Nov 16, 2026.

Industries' Descriptions

@Biotechnology (-8.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
LXEO
Daily Signal:
Gain/Loss:
MLYS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AMDD23.981.30
+5.73%
Direxion Daily AMD Bear 1X ETF (AMDD)
TRUH30.330.73
+2.46%
VanEck Healthcare TruSector ETF (TRUH)
GLIN43.74-0.28
-0.64%
VanEck India Growth Leaders ETF (GLIN)
XSHQ45.25-0.71
-1.54%
Invesco S&P SmallCap Quality ETF (XSHQ)
GFLW32.78-0.77
-2.30%
VictoryShares Free Cash Flow Growth ETF (GFLW)

MLYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with NKTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLYS
1D Price
Change %
MLYS100%
-1.14%
NKTX - MLYS
42%
Loosely correlated
-3.33%
COGT - MLYS
41%
Loosely correlated
+0.21%
TSHA - MLYS
40%
Loosely correlated
-1.96%
LXEO - MLYS
40%
Loosely correlated
-4.01%
DNLI - MLYS
40%
Loosely correlated
-2.88%
More